Related Experiment Video
Updated: Mar 10, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Cardioversion Of Atrial Fibrillation And Oral Anticoagulation
1Heart Center, Turku University Hospital and University of Turku, Turku, Finland.
Insights
Cardioversion for atrial fibrillation carries a risk of thromboembolic events, particularly within the first week. Early anticoagulation is crucial, even for low-risk patients, if cardioversion is delayed.
Area of Science:
- Cardiology
- Thrombosis Research
Background:
- Thromboembolic events are a significant risk during cardioversion for atrial fibrillation.
- Thrombus formation can occur rapidly, within 48 hours of atrial fibrillation onset.
- Increased stroke risk is associated with pre-existing stroke risk factors.
Purpose of the Study:
- To evaluate the timing and necessity of anticoagulation in patients undergoing cardioversion for atrial fibrillation.
- To assess the impact of delayed cardioversion on thromboembolic event risk.
- To inform guidelines regarding anticoagulation strategies for atrial fibrillation cardioversion.
Main Methods:
- Review of current guidelines and literature on cardioversion and anticoagulation.
- Analysis of thromboembolic event occurrence in relation to cardioversion timing.
- Evaluation of stroke risk factors and their influence on anticoagulation recommendations.
Main Results:
- The majority of thromboembolic events post-cardioversion occur within the first week.
- Delayed cardioversion, especially beyond 12 hours, significantly increases stroke risk.
- Current guidelines recommend anticoagulation for moderate-to-high risk patients undergoing cardioversion.
Conclusions:
- Early anticoagulation is essential for patients undergoing cardioversion for atrial fibrillation.
- Short-term anticoagulation should be considered for low CHA2DS2-VASc score patients if cardioversion is delayed (12-48 hours).
- Adherence to timely anticoagulation protocols can mitigate the risk of stroke associated with cardioversion.
Abstract:
The risk of thromboembolic events is a major concern in cardioversion of atrial fibrillation. The vast majority of these events occur in the first week following cardioversion. Processes promoting thrombus formation occur early and thrombus may appear in the left atrium within 48 hours of atrial fibrillation. The risk of thromboembolic events also increases with the presence of stroke risk factors. Thus, the current guidelines recommend that also patients with acute atrial fibrillation should undergo cardioversion under cover of unfractionated or low-molecular weight heparin followed by oral anticoagulation for at least 4 weeks in patients at moderate-to-high risk for stroke. Delay of cardioversion < 12 hours from the symptom onset seems to cause a marked increase in the risk of stroke. Thus, short term anticoagulation should be considered also for patients with a low CHA2DS2VASc score if the delay to cardioversion is 12-48 hours.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
01:29Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:25Dysrhythmias VI: Management of Dysrhythmias
01:29Venous Thrombosis III: Interprofessional Care